Advances of metallodrug-amyloid β aggregation inhibitors for therapeutic intervention in neurodegenerative diseases: Evaluation of their mechanistic insights and neurotoxicity

•Transition metal complexes have demonstrated significant potential to inhibit the aggregation as well as induced cytotoxicity of the amyloid-β (Aβ) peptide in vitro.•The metal complexes exhibit multifold enhanced inhibition activity of amyloid aggregation as compared to their parent or free ligand scaffolds.•Inhibition of aggregation occurs as a result of dual binding modes via hydrophobic and hydrogen-bonding interactions of the ligand framework with the Aβ peptide.•The neurotoxic assessment revealed that most of the transition metal complexes inhibit Aβ42 fibrillation without causing damage to brain cells in vitro and in vivo.